Old formula, new Rx: The journey of PHY906 as cancer adjuvant therapy  by Liu, Shwu-Huey & Cheng, Yung-Chi
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Ethnopharmacological  relevance:  PHY906,  is  a decoction  of  a mixture  of  the  four  herbs  Scutellaria  baicalensis
Geori,  Glycyrrhiza  uralensis  Fisch,  Paeonia  lactiﬂora  Pall,  and  Ziziphus  jujuba  Mill.  A  combination  of  these
four  herbs  has  been  in  continuous  use  in traditional  Chinese  medicine  for over  1800  years  for  treating  a
variety  of  gastrointestinal  distress  such  as  diarrhea,  cramps,  nausea,  vomiting  etc.
Aim  of  the  study:  Preclinical  and  clinical  studies  to  ﬁnd  PHY906  enhances  the  therapeutic  indices  of  a
broad  spectrum  of  anticancer  agents.
Materials  and  methods:  Using  various  mouse  tumor  xenograft  and  allograft  models,  PHY906  has  been
shown  to  enhance  the  chemotherapeutic  efﬁcacy  of  a  variety  of anticancer  agents  in  various  cancers.
The  PHY906  clinical  program  consists  of  ﬁve  trials  in  three  different  types  of  cancers  in  both  the  United
States  and  Taiwan.  To  date,  approximately  150  subjects  have  received  PHY906  in combination  with
chemotherapy  in these  ﬁve  clinical  studies.
Results:  Preclinical  studies  have  shown  that  PHY906  enhances  the  therapeutic  indices  of a broad  spec-
trum  of  anticancer  agents.  These  ﬁndings  have  been  examined  in  clinical  studies  for  colorectal,  liver, and
pancreatic cancers  when  PHY906  is used  as an  adjuvant  to chemotherapy  and  the  results  were  promising;
i.e.  PHY906  could  reduce  chemotherapy-induced  toxicities  and/or  increase  chemotherapeutic  efﬁcacy.
Furthermore,  PHY906  did  not  affect  the  pharmacokinetics  of the  chemotherapeutic  agents  used.  Some
information  has  been  obtained  regarding  the  mechanism  of  action  of  PHY906  in  preclinical  studies.  A com-
prehensive platform,  PhytomicsQC  that integrates  chemical  and  biological  ﬁngerprints  together  with  a
novel biostatistical  methodology  has  been  developed  to  assess  the  quality  of  different  batches  of  PHY906.
Conclusions:  Over  a  ten-year  period,  the  multiplex  technology  “PhytomicsQC”  has  been  used to  show
batch-to-batch  consistency  of  PHY906  production.  Advanced  clinical  trials  are  ongoing  to  demonstrate
the  effectiveness  of  PHY906  as  adjuvant  therapy  for cancer  patients  undergoing  chemotherapy.. Introduction
Cancer is the second overall cause of death in the U.S. and many
nmet needs exist within the ﬁeld. Medical oncology has had a
reat impact in changing the practice of medicine in the past sev-
ral decades by developing a few curative treatments for a variety
f previously fatal malignancies. However, some commonly used
rugs could have better therapeutic indices and greater potential
Abbreviations: AE, adverse event; APC, advanced pancreatic cancer; B.I.D., twice
er day; CRC, colorectal cancer; DLT, dose-limiting toxicity; GAP, Good Agricultural
ractices; GCP, Good Clinical Practice; GI, gastrointestinal; GLP, Good Laboratory
ractice; GMP, Good Manufacturing Practice; HCC, hepatocellular cancer; IND,
nvestigational New Drug; IP, intraperitoneal; mOS, median overall survival; MTD,
aximum tolerated dose; NDA, new drug application; OS, overall survival; PR, par-
ial response; SAE, serious adverse event; SD, stable disease; TIC, three times per
ay; TTP, time for tumor progression.
∗ Corresponding author. Tel.: +1 203 7857118; fax: +1 203 7857129.
E-mail address: yccheng@yale.edu (Y.-C. Cheng).
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Open access under CC BY-NC-ND license.© 2012 Elsevier Ireland Ltd. 
for success if their harmful side effects could be reduced. Targeted
therapy has become one of the main approaches for increasing a
drug’s therapeutic index as it was  thought to improve the antitumor
selectivity and reduces the side-effects of treatment by targeting
a speciﬁc gene, enzyme or receptor. However, side effects from
chemotherapy and targeted therapy are prevalent and such toxici-
ties not only can prevent a patient from receiving the most effective
chemotherapeutic doses, but also can adversely impact a patient’s
quality-of-life. Common side effects associated with chemotherapy
and targeted therapy are gastrointestinal ailments such as diarrhea,
nausea, and vomiting, as well as hand-foot syndrome, etc. (Forman,
1994; Llovet et al., 2008; Cheng et al., 2009; Chen et al., 2010). Any
medicine that is able to ameliorate these multiple adverse effects
without compromising antitumor efﬁcacy of a drug would improve
the quality of life for patients and also enhance the therapeutic
Open access under CC BY-NC-ND license.indices of anti-neoplastic medicines (Calabresi and Chabner, 1996;
Eisenberg et al., 1998; Armstrong and Gilbert, 2008).
Herbal medicines have been commonly used by cancer patients
in Asia to combat various diseases (Quimby, 2007; Konkimalla
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Table 1
Preclinical studies of PHY906 with chemotherapeutic agents.
Chemotherapeutic agent Indication
CPT-11 Colorectal cancer
Capecitabine Colorectal and liver cancer
CPT-11/5-FU/LV Colorectal cancer
VP-16 Lung cancer
L-OddC Leukemia, pancreatic cancer
Gemcitabine Pancreatic cancer
Oxaliplatin Colorectal cancer
Sorafenib Renal and liver cancer
in that it either enhances the chemotherapeutic efﬁcacy or reduces
the toxicities, or both, of a variety of anticancer agents including
5-ﬂuorouracil (5-FU), VP-16 (Etopophos®, Vepesid®), irinotecan
(CPT-11, Camptosar®), L-OddC (troxacitabine, Troxatyl®), L-FMAUS.-H. Liu, Y.-C. Cheng / Journal of E
nd Efferth, 2008; Liu et al., 2010; Liu and Saif, 2012). PHY906,
 pharmaceutical grade of traditional Chinese herbal formula-
ion Huang-Qin-Tang (HQT), composed of four distinct herbs: the
oots of Scutellaria baicalensis Georgi.  (scute), Glycyrrhiza uralen-
is Fisch. (licorice) and Paeonia lactiﬂora Pall.(peony), and the fruit
f Ziziphus jujuba Mill (Chinese date), has been documented for
early 1800 years for treating common gastrointestinal distress,
ncluding diarrhea, abdominal spasms, fever, headache, vomit-
ng, nausea, extreme thirst, and subcardiac distention. Each of the
our component herbs possesses a distinct pharmacological pro-
le; these include anticancer and antiviral activity, hematological
nd immunological modulation, analgesic activity, liver protection,
nd appetite improvement. Teams led by Professor Yung-Chi Cheng
t the Yale University School of Medicine and PhytoCeutica, Inc.
ave explored PHY906 as an adjuvant for cancer chemotherapy and
argeted therapy. With the unique and deﬁned procedures for its
reparation, characterization, and quality control, PHY906 is differ-
nt from HQT that is currently available in the market. Preclinical
tudies have indicated that PHY906 enhances the antitumor efﬁca-
ies of a broad-spectrum of anticancer agents in a variety of murine
enograft and allograft models (Liu et al., 2000, 2001, 2002, 2003,
004, 2006, 2007) whereas HQT did not show such activity.
In contrast to the traditional single molecule-single target
pproach in drug development, the mechanism of action of PHY906
s multifactorial. These different mechanisms may  be mediated by
ne or more of the constituent chemicals of PHY906. In vivo stud-
es with CPT-11 (Irinotecan, Camptosar®) indicated that PHY906
lso can reduce the dose-limiting GI side effect (severe late-onset
iarrhea) of CPT-11. In addition to the anti-inﬂammatory activity
f PHY906 that is mediated through at least three mechanisms
y different chemical constituents of PHY906 or their metabo-
ites of PHY906 (Ye et al., 2007; Zhang et al., 2010), PHY906 can
lso restore damaged intestinal epithelium through promotion of
ntestinal progenitor or stem cell growth, mediated by increasing
f several Wnt  signaling components as well as potentiation of Wnt
ction (Lam et al., 2007, 2009, 2010). Several phase I/II clinical tri-
ls have been conducted in U.S. to explore the toxicity and clinical
fﬁcacy of PHY906. The results were highly encouraging. PHY906
as shown to provide cytoprotective effects without dampening
he anti-tumor activity of chemotherapeutic agents in liver, pan-
reatic, and colorectal cancer patients under chemotherapy (Yen
t al., 2009; Saif et al., 2007; Saif, 2008a,b; Saif et al., 2009, 2010a,b;
arrell and Kummar, 2003; Kummar et al., 2011).To ensure that
onsistent batches of PHY906 can be made, a comprehensive tech-
ology platform termed “PhytomicsQC” that integrated chemical
ngerprints and biological ﬁngerprints, analysed by novel statisti-
al analysis, was developed to evaluate different batches of PHY906.
t was demonstrated PHY906 can be made with consistency (Tilton
t al., 2010).
. Preclinical studies of PHY906 in murine tumor models
CPT-11, an inhibitor of topoisomerase I, is a widely used agent
or the treatment of colorectal cancer. The dose-limiting side effect
f CPT-11 is severe late-onset diarrhea (Goldber and Erlichman,
988; Bleiberg and Cvitkovic, 1996). Based on traditional anti-
astrointestinal ailment claims in Chinese medicine documents,
HY906 offered a possibility for reducing the severe diarrhea
ssociated with CPT-11 treatment, but only if PHY906 did not com-
romise CPT-11 antitumor effectiveness.
BDF-1 mice bearing murine colon 38 tumor were used as a sur-
ogate system to test the above hypothesis. Mice were treated
ith a single dose of CPT-11 at its maximum tolerated dose of
60 mg/kg intraperitoneally in the presence or absence of twice
aily gavage administration of PHY906 (125, 250, or 500 mg/kg)Taxol Lung, breast and ovarian cancer
Sunitinib Renal and liver cancer
for 4 days. The animals were evaluated for tumor size, changes in
body weight, mortality, and hematologic toxicity. The results indi-
cated that PHY906 was able to reduce CPT-11-induced body weight
loss in a dose-dependent manner with maximum protective effect
occurring at a PHY906 dose of 500 mg/kg (p < 0.01).
Mortality data from the same colon 38 allografts indicated
that PHY906 alone does not exhibit any signiﬁcant toxicity; 100%
of the tumor-bearing mice survived with PHY906 treatment. In
contrast, treatment with a single dose of CPT-11 resulted in 60%
survival of the tumor-bearing mice after 14 days. However, this
survival rate dramatically improved to 100% after receiving 4 days
of PHY906 treatment in combination with CPT-11 (Kummar et al.,
2011) (Fig. 1). This result suggested that PHY906 treatment can
indeed protect mice against mortality induced by a single high dose
of CPT-11.
Surprisingly, it appears that PHY906 has a dual effect on CPT-
11: not only does it reduce CPT-11-induced toxicities such as
bodyweight loss and mortality, but it also potentiates the anti-
tumor activity of CPT-11 (Fig. 2A). The studies were expanded to
other chemotherapeutic agents that have mechanisms of antitumor
action different from that of CPT-11. In addition to the colorec-
tal cancer model, the study also has been expanded into other
tumor models such as hepatocellular carcinoma and pancreatic
cancer (Fig. 2B and C), for which successful treatments do not
exist. PHY906 has been shown to be a broad-spectrum adjuvantFig. 1. Kaplan–Meier survival plot of Colon 38 bearing BDF-1 mice treated with
CPT-11 vs. PHY906 plus CPT-11.
With permission from Kummar et al. (2011).
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colon38/BDF1 model system. Table 2 shows that both Scutellaria
baicalensis Georgi (S) and Paeonia lactiﬂora Pall. (P) play signiﬁcant
roles in enhancing the antitumor activity of CPT-11 whereas Gly-
cyrrhiza uralensis Fisch.(G) and Ziziphus jujuba Mill. (Z) play only
Table 2
Summary of the effects of removing single herbs from the PHY906 formulation on (1)
potentiation of antitumor activity, (2) reduction body weight loss, and (3) prevention
of  mortality.
Herbs in formulation Potentiation of
antitumor effect
Reduction of
body weight loss
Prevention of
mortality
S P G Z
+ + + + ++ ++ ++
− + + + − − +
+ − + + − ++ ++Fig. 2. PHY906 enhances antitumor activity of
ith  permission from (1) Lam et al. (2010), (2) Yen et al. (2009), (3) Liu et al. (2004
clevudine, Revovir®), paclitaxel (Taxol®), oxaliplatin (Eloxatin®),
apecitabine (Xeloda®), thalidomide (Thalomid®), gemcitabine
Gemzar®), sunitinib (Sutent®), and sorafenib (Nexavar®) (as
epicted in Table 1) (Liu et al., 2000, 2002, 2006, 2007).
In the treatment of cancer, rarely is a single agent effective;
ather, multiple agents and/or treatment modalities are used.
he most commonly used ﬁrst-line chemotherapies for advanced
olorectal carcinoma are FOLFIRI [folinic acid (leucovorin, LV), ﬂu-
rouracil (5-FU), and irinotecan (CPT-11)], and FOLFOX [LV, 5-FU,
nd oxaliplatin] regimens. The effectiveness of such combination
reatments is often limited by the occurrence of severe side effects.
igh-dose loperamide is a standard treatment for CPT-11-induced
iarrhea in Europe and the US, but the success of this approach
s limited (Rothenberg et al., 1999). Other side effects that occur
ith the use of the FOLFIRI or FOLFOX regimen include nausea
nd vomiting (Douillard et al., 2000). Therefore, the management
f a multiplicity of side effects may  be necessary to increase both
he patient’s response to therapy and quality of life while under
reatment and multiple agents are often used to treat multiple
ide effects. In addition to the monotherapies listed in Table 1,
HY906 also has been shown to increase the therapeutic indexes
f various drug combinations including 5-FU/LV, CPT-11/5-FU/LV,
xaliplatin/5-FU/LV, and gemcitabine/oxaliplatin. In addition to
PT-11, PHY906 also reduces the chemotherapy-induced mortality
f the oxaliplatin/5-FU/LV combination in Colon 38 tumor-bearing
ice. In vivo studies indicated that PHY906 did not have protective
ffects on chemotherapy-induced myelosuppression.
To determine if PHY906 affected the metabolism of can-
idate cancer chemotherapeutic agents, the pharmacokinetics
f the chemotherapeutic drugs was studied in tumor-bearing
ice. The effects of PHY906 on the pharmacokinetics of CTP-11,otherapeutic agents in various animal models.
capecitabine, gemcitabine, and sorafenib have been examined in
colorectal cancer, hepatocellular carcinoma, and pancreatic can-
cer animal models, respectively. Results of the effect indicated that
PHY906 did not affect the metabolism of these chemotherapeutic
agents or their corresponding metabolites (Liu et al., 2002, 2004,
2007).
All four herbs of the PHY906 formulation are necessary for its
biological effects to be manifested. Experiments were conducted
in which the effectiveness of herbal formulations that lacked one
of the constituent herbs were compared with PHY906 itself in
affecting (a) antitumor activity of CPT-11, (b) body weight loss
induced by CPT-11, and (c) survival of CPT-11-treated mice in the+ + − + + − ++
+ + + − ++ − −
++, signiﬁcant effect; +, possible effect; −, no effect.
Liu  et al. (2002).
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inor roles. In terms of protecting animals from body weight loss
nduced by CPT-11, S and G appear to be the most important herbs in
he PHY906 formulation followed by Z; P plays no role. Other stud-
es have revealed that not only must all four herbs of the PHY906
ormulation be present, but also that they must be in the proper
atio for the biological effects of PHY906 to be manifested. Although
HY906 is a derivative of traditional Chinese medicine HQT, the
herapeutic activities shown with PHY906 are not manifested by
ommercially available HQT examined.
. Mechanism of action of PHY906
.1. Reduction in chemotherapy-induced toxicities
Preclinical studies indicated that PHY906 could enhance the
nti-cancer activity of CPT-11 while decreasing CPT-11-induced
eight loss and mortality. The cause of the severe delayed-
nset diarrheal toxicity of CPT-11 is the accumulation of its
ctive metabolite, SN-38, in the gastrointestinal (GI) system. CPT-
1 is converted to its active metabolite, SN38, by hepatic and
ntestinal carboxyesterases. SN38 is then metabolized by hepatic
DP–glucuronyltransferase to form an inactive metabolite, SN38G,
nd excreted through bile duct into the intestine. Intestinal bac-
erial -glucuronidase can then convert SN38G back into active
N38 which causes direct damage to the intestine and leads to
ntestinal inﬂammation. Studies indicated that PHY906 did not
ave major impact on the activation of SN38 by intestinal bacterial
lucuronidase as PHY906 did not protect the onset of CPT-11-
nduced damage to the intestine. Treatment with CPT-11 alone
aused destruction of the normal jejeunal mucosal architecture,
nlarged cell size with less condensed nuclei, inﬂammatory cel-
ular inﬁltration, and increased number of lysozyme vesicles in
he paneth cells by day 2, and these effects increased by day
 after CPT-11 administration. Although PHY906 did not protect
gainst the initial damage and apoptosis triggered by CPT-11 in the
ntestine by day 2, PHY906 restored the intestinal epithelium by
romoting the re-growth of intestinal progenitor/stem cells and
ncreasing several Wnt  signaling components after CPT-11 treat-
ent on day 4 as well as potentiating Wnt  action (Lam et al., 2009,
010). In addition to the pathological changes associated with the
nﬁltration of inﬂammatory cells (neutrophils and macrophages),11 gastrointestinal injury.
CPT-11 was  also found to increase TNF- in the intestine on day
4. PHY906 exhibited anti-inﬂammatory effects by decreasing the
inﬁltration of neutrophils/macrophages, decreasing TNF- expres-
sion in the intestine, and decreasing pro-inﬂammatory cytokine
levels in plasma. The mechanism could be mediated through the
inhibition of the NF-kB pathway and direct inhibition of Cox-2 and
iNOS activities by various constituent chemicals or metabolites of
PHY906 (Fig. 3).
The expression of other pro-inﬂammatory cytokines involved
in the CPT-11-induced inﬂammatory response could also be sup-
pressed by PHY906 treatment. Other in vitro preclinical studies
indicated that PHY906 inhibited the receptors of Tachykinin NK1
and the opiate delta receptor which have been reported to be
causative factors for diarrhea, vomiting, nausea, and pain (Liu et al.,
2004).
3.2. Enhancement of antitumor activities
PHY906 was found to enhance the antitumor activity of various
chemotherapeutic agents, including CPT-11. In a further effort to
elucidate the mechanism(s) by which PHY906 exerts such activity,
gene expressions in normal liver, spleen, and tumor from Colon 38-
bearing BDF-1 mice that were administered CPT-11, PHY906 alone,
or co-administered with PHY906 and CPT-11 were compared.
Among 25,000 genes that were monitored, the gene expression
in tumors was  very different from that seen in normal liver or
spleen. CPT-11 was  found to have a major impact on the gene
expression of the NF-B family as well as on apoptosis whereas
PHY906 alone had no signiﬁcant effect on such pathways. However,
PHY906 was  shown to reverse the down-regulation of the expres-
sion of genes related to innate immune responses resulting from
CTP-11 treatment. The combination therapy of PHY906 and CPT-
11 predominantly affected pathways associated with the immune
switch from chronic to acute inﬂammation. It was  also found that
PHY906 activated the IRF-5/Myd88 pathways and reversed the sup-
pression of the STAT-1/IRF-1 pathway. The results indicated that
PHY906 could reduce inﬂammation when given alone. PHY906
was  also able to enhance acute pro-inﬂammatory processes within
the tumor when given in combination with CPT-11 (Wang et al.,
2011).
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Table 3
Clinical studies of PHY906.
Type of cancer Protocol number Regimen(s) Study site
Colorectal cancer PHY906-2000-1 CPT-11/5-FU/LV + PHY906 vs. CPT-11/5-FU/LV + placebo 1. Yale Cancer Center, CT
2.  VA Health System, West Haven, CT
3.  Saint Francis Medical Center, NE
4. Cornell Weill Medical College, NY
5. Cancer Center of Carolinas, SC
Colorectal cancer HIC0808004167 CPT-11 + PHY906 Yale Cancer Center, CT
Hepatocellular carcinoma PHY906-2002-1 Capecitabine + PHY906 1. City of Hope Cancer Center, CA
PHY906-2002-1-T 2. Standford School of Medicine, CA
3. Yale Cancer Center, CT
4.  VA Health System, West Haven, CT
5.  National Institute of Cancer Research, Taiwan
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. PHY906 clinical trials
To date, the PHY906 clinical program has launched ﬁve trials in
hree different types of cancer in both the US and Taiwan: two phase
 studies in advanced colorectal cancer (CRC), one phase I/II study
n advanced hepatocellular carcinoma (HCC), one phase II study
n advanced hepatocellular carcinoma, and one phase I/II study in
dvanced pancreatic cancer (APC). A total of 150 patients received
HY906 administered orally as 200 mg  capsules in various dose
egimens (Table 3).
.1. Colorectal cancer
Colorectal cancer (CRC) is the second leading cause of death
rom cancer with more than 101,340 new cases and almost 49,380
eaths expected to occur in US in 2011. In 2000, the “Saltz reg-
men” (also known as IFL) that consists of the combination of
PT-11, 5-FU, and LV was accepted as ﬁrst-line chemotherapy for
dvanced colorectal cancer (Saltz et al., 2000). According to the data
eported by Saltz et al., 31% of patients who received the IFL reg-
men experienced a grade 3 or higher diarrheal toxicity, 13% had
ausea, 10% had vomiting, and 10% experienced fatigue, as sum-
arized in Table 4 (Saltz et al., 2007). Currently, the most popular
rst-line chemotherapies for CRC are either CPT-11-based, i.e. CPT-
1/5-FU/LV (FOLFIRI), or oxaliplatin-based, i.e. oxaliplatin/5-FU/LV
FOLFOX) (Karaca-Mandic et al., 2011).
The ﬁrst clinical trial of PHY906 was a phase I/IIa multi-
enter, double-blind, randomized, placebo-controlled, crossover,
ose-escalation, safety study in combination with CPT-11/5-FU/LV
IFL) or with CPT-11 alone for chemotherapy naïve patients with
dvanced colorectal cancer. Patients were evaluated for safety, tol-
rability, and efﬁcacy in alleviating diarrhea after receiving IFL
nd PHY906 (400 mg  or 800 mg,  tic)  combination chemotherapy.
atients receiving the IFL regimen were administered CPT-11 at a
eekly dose of 125 mg/m2, followed by leucovorin at 20 mg/m2
nd 5-FU at a dose of 500 mg/m2. Chemotherapy was  administered
able 4
HY906 reduced the common non-hematological grade 3/4 toxicity in patients with
olorectal cancer.
Non-hematological
Grade 3/4 toxicities
CPT-11/FU/LV
(N = 630)a
PHY906 + CPT-11/FU/LV
(N = 14)b
Diarrhea 31% 0
Vomiting 10% 0
Nausea 13% 7%
Fatigue 10% 0
a Saltz et al. (2007).
b Kummar et al. (2011).National Institute of Cancer Research, Taiwan
Yale Cancer Center, CT
weekly for 4 weeks, followed by a two-week rest period. Cycles
were repeated every 6 weeks. Patients were randomized to one of
two  cohorts, with 50% of the patients receiving PHY906 during the
ﬁrst cycle of chemotherapy and placebo with the second cycle. Eigh-
teen patients were enrolled in the study: 17 patients received the
IFL regimen and one patient received CPT-11 monotherapy. Among
the 17 patients receiving the IFL regimen, 9 of 13 patients in cohort I
(69.2%), and 3 of 4 patients in cohort II (60.0%) completed the study
(Farrell and Kummar, 2003; Kummar et al., 2011).
Eleven patients in cohort 1 and two patients in cohort 2 experi-
enced treatment-related side effects during treatments with either
PHY906 or placebo. No patients receiving PHY906 plus chemother-
apy experienced treatment-related, life-threatening (grade 4)
toxicity during treatment. In contrast, two  of 16 patients (6.3%)
experienced treatment-related, life-threatening (grade 4) adverse
events (neutropenia and GI hemorrhage) during treatment with
placebo plus chemotherapy. The study also showed that fewer
patients required anti-diarrheal supplements while receiving
PHY906 as compared to placebo, and that there was  indeed a reduc-
tion in the overall incidence of grade 3 or 4 diarrhea. In addition,
there was  also a trend towards lower frequency and severity of
vomiting for cycles in which patients received PHY906 as opposed
to placebo (Table 4) (Kummar et al., 2011).
The effect of PHY906 on the pharmacokinetics of 5-ﬂuorouracil
and CPT-11 were investigated. Co-administration of PHY906 along
with 5-FU or CPT-11 did not alter the pharmacokinetic parameters
of 5-FU or CPT-11 nor did it affect the conversion of CPT-11 to its
active metabolite SN-38. The study was  terminated early due slow
accrual, because during the trial the FOLFOX regimen replaced IFL
as ﬁrst-line standard treatment for colorectal cancer. At study ter-
mination, 15 patients were evaluable for efﬁcacy; 13 patients (87%)
exhibited stable disease after two  cycles of combination treatment.
Although PHY906 may  have a potentiating effect on the clinical efﬁ-
cacy of the IFL regimen, it is difﬁcult to make ﬁrm conclusions from
the small number of patients in the trial.
A second clinical trial of PHY906 with CPT-11 monotherapy in
heavily treated (with chemotherapy) patients with advanced col-
orectal cancer was  conducted by Saif et al. at the Yale Cancer Center.
CPT-11 was  administered once every two  weeks, beginning at a
dose of 180 mg/m2 and escalating to 215 mg/m2 in dose level 4
and to 250 mg/m2 in dose level 5. PHY906 was  administered orally
twice daily on days 1-4 every two weeks from cycle 2 (cycle 1 in
dose levels 4 and 5) starting at 1200 mg  twice per day and esca-
lating to 1800 mg  twice daily in dose level 2, and 2400 mg  twice
daily in dose levels 3 through 5 (Table 5) (Alsamarai et al., 2010).
The primary objective of the phase I study was to determine the
maximum tolerated dose (MTD) of PHY906 when combined with
a standard dose of CPT-11. The primary objective of the phase II
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Table 5
Dose escalation of CPT-11 and PHY906 in the phase i clinical trial in patients with colorectal cancer.
Dose level CPT-11 (Irinotecan, Camptosar®) PHY906
1 180 mg/m2 intravenously over 90 min  on day 1 every 2 weeks from cycle 1 1200 mg twice a day for 4 days on days 1–4 every 2 weeks from cycle 2
2 180  mg/m2 intravenously over 90 min  on day 1 every 2 weeks from cycle 1 1800 mg twice a day for 4 days on days 1–4 every 2 weeks from cycle 2
3 180  mg/m2 intravenously over 90 min  on day 1 every 2 weeks from cycle 1 2400 mg twice a day for 4 days on days 1–4 every 2 weeks from cycle 2
4  215 mg/m2 intravenously over 90 min  on day 1 every 2 weeks from cycle 1 2400 mg twice a day for 4 days on days 1–4 every 2 weeks from cycle 2
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launched in Taiwan in heavily-treated patients with advanced or
metastatic hepatocellular carcinoma and Child-Pugh A classiﬁca-
tion. The treatment consists of PHY906 800 mg bid on days 1–4,
8–11 and capecitabine 750 mg/m2 bid on days 1–14, every 21 days.
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lsamarai et al. (2010).
tudy was to determine the response rate in patients treated at the
ose level established in the phase I study. Both pharmacokinetic
nd pharmacodynamic analyses were included in this study.
A total of 25 patients were accrued to the study and treatment
ad reached dose level 4 (CPT-11, 215 mg/m2 day 1 and PHY906
400 mg  bid,  days 1–4) when the phase I study was completed. The
ommonly used dose of CPT-11 in colorectal cancer chemother-
py is 180 mg/m2 with diarrhea as a dose-limiting toxicity. In this
tudy, no grade 3 or higher diarrhea was noted at any dose level
f CPT-11 (180–250 mg/m2). These results suggested that PHY906
ight be able to expand patients’ tolerability to CPT-11. Pharma-
okinetic analyses showed that PHY906, up to a total dose of 4.8
rams daily, did not interfere with the metabolism or pharmacoki-
etics of CPT-11 or its metabolites SN 38 and SN 38G (Alsamarai
t al., 2010). Using LC/MS/MS technology, PHY906 and its metabo-
ites were identiﬁed in the plasma of these patients with metastatic
olorectal cancer (Zhang et al., 2010).
.2. Hepatocellular cancer
Hepatocellular carcinoma (HCC) is the most common form of
rimary liver cancer. It arises in hepatocytes, the major cell type
f the liver. Hepatitis C (HCV) and hepatitis B (HBV) viruses are
he main viral risk factors for the development of HCC. To a lesser
xtent, alcoholic cirrhosis and long term exposure to aﬂatoxin also
ncrease the risk of developing HCC (El-Serag and Mason, 1999).
CC is associated with high mortality, high morbidity and a poor
rognosis. The 5-year survival rate for HCC is 5% (American Cancer
ociety, 2011). For patients with unresectable HCC, overall median
urvival ranges from between 2 and 4.1 months (Alsowmely and
odgson, 2002). The only FDA-approved medicine for HCC is
orafenib (Nexavar®) (Llovet et al., 2008; Sandhu et al., 2008).
Two open-labelled clinical studies of PHY906 with capecitabine
ere conducted in patients with unresectable HCC. The ﬁrst study
as a phase I/II study with most of patients (93%) being enrolled in
he US whereas the second study was a phase II study in Taiwan.
he phase I/II trial was a multicenter, open-label, dose-escalation,
afety and efﬁcacy study of PHY906 plus capecitabine in patients
ith advanced, unresectable hepatocellular carcinoma. Three dose
egimens were used in the study and 45 subjects were enrolled in
ve medical centers (four in the US and one in Taiwan), as listed in
able 3. Capecitabine (750 or 1000 mg/m2 bid)  was  administered
rally starting on day 1 and continued for 14 consecutive days
ollowed by 7 days rest. PHY906 (600, 800, or 1000 mg  bid)  was
dministered orally on days 1–4 and 8–11 of each 21-day course.
orty-two patients with HCC were enrolled at the US sites: 18 in
hase I and 24 in phase II; while three patients from Taiwan site
ere enrolled in the phase II study. The results from these three
aiwanese patients were excluded from the data analysis as the
nrollment criteria were slightly different from those for the US
ites.Among the 42 US patients, 25 patients (59.5%) were classiﬁed as
hild-Pugh A and 17 (40.5%) as Child-Pugh B. Three cohorts were
nvolved in the phase I study: capecitabine 1000 mg/m2 bid plus
HY906 1000 mg  bid; capecitabine 750 mg/m2 bid plus PHY906le 1 2400 mg twice a day for 4 days on days 1–4 every 2 weeks from cycle 2
600 mg  bid; capecitabine 750 mg/m2 bid plus PHY906 800 mg bid.
Forty of the 42 enrolled patients (95.2%) enrolled in the US  experi-
enced adverse events (AEs), and 10 of the 42 (23.8%) experienced
serious adverse events (SAEs). The combination of PHY906 (600 mg
or 800 mg  bid)  and capecitabine (750 mg/m2 bid) was well toler-
ated (N = 39). The most frequently experienced grade 3 drug-related
AEs were mucositis/stomatis (7.7%), dehydration (5.1%), neutrope-
nia (2.6%), hyperbilirubinemia (2.6%), and hand-foot skin reaction
(2.6%). No patients experienced drug-related grade 4 or 5 toxicities.
The dose used in phase II was capecitabine 750 mg/m2 bid and
PHY906 800 mg  bid.  To qualify for efﬁcacy evaluation, patients must
have completed two  courses of treatment, must have had a CT
scan and must have received at least 75% of the recommended
amount of study drug. The disease control rate was  65.2%; 8.7% had
moderate response (MR) and 56.5% exhibited stable disease (SD).
Median time to progression (TTP) was 3.4 months and median over-
all survival (OS) was  9.2 months. Seventy-four percent (N = 20) of
the 27 efﬁcacy-evaluable patients were classiﬁed as Child-Pugh A.
Median OS values for Child-Pugh A and Child-Pugh B patients were
10.9 and 6.5 months, respectively. The 12-month survival rate was
51% for Child Pugh A patients and 29% for Child Pugh B patients.
Although the patient number was small, the data implied that the
combination therapy of PHY906 with capecitabine might have a
beneﬁcial effect on the Asian subgroup with median OS of 16.5
months whereas the OS for non-Asian subgroups was 6.2 months
(p = 0.03). The subgroup analysis indicated that the median OS for
Asian Child-Pugh A patients was 16.5 months as compared to 6.7
months for non-Asian Child-Pugh A patients (p = 0.05) as shown in
Fig. 4. Patients’ quality of life did not deteriorate signiﬁcantly during
treatment (Liu et al., 2006; Rose et al., 2007; Yen et al., 2009).
Based on the encouraging survival results on Asian Child-Pugh
A patients, a phase II study of PHY906 plus capecitabine has beenFig. 4. Kaplan–Meier survival curve of Asian vs. non-Asian Child-Pugh A patients
treated with PHY906 (600 or 800 mg) plus capecitabine (750 mg/m2) in patients
with  hepatocellular carcinoma.
With permission from Yen et al. (2009).
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he primary end-point of this open-label phase II study is to deter-
ine the 6-month survival rate.
.3. Pancreatic cancer
Pancreatic cancer is the eighth most common cause of death
rom cancer worldwide and is the fourth leading cause of cancer
eaths in the US (American Cancer Society, 2011). In comparison
o other gastrointestinal tract cancers, advances in the treatment
f pancreatic cancer have been very limited (Ozols et al., 2007).
his fact is emphasized by the disappointing results of a num-
er of recent randomized trials. Patients whose pancreatic cancer
s untreated have a 3–4 month median survival and less than 5%
f those who receive treatment survive 5 years. Gemcitabine has
een the standard treatment for advanced pancreatic cancer for the
ast decade. This cytidine analog has served as the basis for many
hemotherapeutic regimens, but until recently, such combinations
ave failed to surpass gemcitabine monotherapy in effectiveness
nd even these newer combinations have only shown modest
mprovement (Burris et al., 1997; Berlin et al., 2002; Chauffert et al.,
008).An open label phase I/II study of PHY906 in combination with
apecitabine in patients with advanced pancreatic and gastroin-
estinal malignancies was concluded at Yale Cancer Center in 2009
Hoimes et al., 2008). Eligible patients with advanced solid tumors
ho had failed standard therapy or for which no standard ther-
py existed were recruited for the phase I study. Patients who had
emcitabine-refractory pancreatic cancer with a performance sta-
us ≤2, and adequate organ function were recruited into this Phase
/II study. In the phase I study, 24 patients were enrolled, including
5 patients with pancreatic cancer, 6 colon cancer, 1 cholangiocar-
inoma, 1 esophageal cancer and 1 unknown primary. The primary
oal of phase I was to determine the maximum tolerated dose
MTD) of capecitabine (1000, 1250, 1500, and 1750 mg/m2 bid in
ombination with a ﬁxed dose of PHY906 (800 mg  bid on days 1–4))
n a 14-day cycle.One patient in the capecitabine 1000 mg/m2 bid
ohort had a dose-limiting toxicity (DLT), (Grade 4 AST/ALT, Grade 3
yponatremia). No further DLTs were observed in the subsequent
ohorts and doses of capecitabine were escalated to 1750 mg/m2
id.  There were no DLTs at the maximum dose level of 1750 mg/m2,
owever, the delivered dose-intensity of capecitabine was  similar
t both the 1750 mg/m2 and 1500 mg/m2 dose levels. Therefore,
he MTD  was deﬁned at 1500 mg/m2 of capecitabine in this dos-
ng schedule with PHY906. One patient (4.2%) achieved a partial
esponse and 13 patients (54.2%) had stable disease that lasted
ore than six weeks (Saif et al., 2010a,b).
In the phase II study, pancreatic cancer patients who were
emcitabine-refractory received capecitabine 1500 mg/m2 bid
ays 1–7 and PHY906 800 mg  bid days 1–4 every two  weeks. The
rimary objective was overall survival (OS). Among 25 enrolled
atients: 25 were evaluable for safety and 22 who received at least
ne cycle were evaluable for efﬁcacy. Predominant AEs included
rade 3 diarrhea (n = 3), grade 3 fatigue (n = 3), and grade 3 HFS
n = 1). Among 22 efﬁcacy evaluable patients, two achieved PR (9%)
nd 10 had stable disease (46%) with a disease control rate of 55%.
ll intent-to-treat patients reached median progression-free sur-
ival (mPFS) of 11 weeks (r: 2–70+) and median overall survival
mOS) of 25 weeks (r: 3.4–78+). For 18 patients who  received ≥ 2
ycles, mPFS was 13 weeks and mOS  was 31 weeks. The 9-month
urvival rate was 37%. The results suggested that PHY906 may
ncrease the therapeutic index of capecitabine by reducing diarrhea
nd hand-foot syndrome (Li et al., 2010; Saif et al., 2008, 2010a,b).. Quality control of PHY906
According to the Guidance for Industry: Botanical Drug Products
ublished by the FDA in June 2004, consistently good quality ofarmacology 140 (2012) 614– 623
the botanical drug product is essential for herbal drug develop-
ment (FDA, 2004). These regulations set forth by the FDA  pertain
not only to quality control of the ﬁnal product, but also to botanical
raw materials, in-process controls during manufacturing and ﬁnal
process validation, especially for the drug substance as a whole. To
sustain and complete initial clinical trials, it is required that suf-
ﬁcient quantities of the botanical drug product be prepared in a
single batch from a single source of the botanical drug substance
and/or raw materials (Chen et al., 2008).
The herbs used in PHY906 formula preparation were carefully
monitored in terms of their growth conditions and levels of fertil-
izers used in order to ensure the highest levels of consistency in
the raw herbs. The consistency and quality of the manufacturing
process of PHY906 drug substance and product conform to Good
Manufacturing Process (GMP) regulations.
For most herbal formulations, current manufacturing quality
control for consistency relies on the measurement of marker com-
pounds contained in single constituent herbs by chromatographic
technologies, such as thin layer chromatography (TLC), gas chro-
matography (GC), or liquid chromatography (LC) with detection
methods such as UV–vis, evaporative light scattering (ELSD), etc.
(Marcus and Grollman, 2002). In most cases, it is not clear whether
or not the marker compounds are responsible for the biological
activity of the formulation. Thus, the value of the determination
of the content of those marker compounds for quality control of
herbal formulations is questionable (Wong et al., 2001).
In addition to traditional analyses, such as heavy metal tests,
microbial tests, pesticide residues, a multi-faceted approach, Phy-
tomicsQC, that integrates (1) high resolution chemical ﬁngerprint
focusing on liquid chromatography/mass spectrometry (LC/MS);
(2) bioresponse ﬁngerprint with genomics technology on differen-
tial cellular gene expression; (3) animal pharmacology for in vivo
validation and (4) a sensitive, quantitatively comparison method,
Phytomics Similarity Index (PSI) has been developed by the joint
efforts of Yale University and PhytoCeutica, Inc. teams to assure the
quality consistency of different manufactured batches of PHY906
(Fig. 5) (Ye et al., 2007; Tilton et al., 2010). This kind of multi-faceted
approach is not only good for the quality control of such medicines,
but also useful for the discovery of new indications or the develop-
ment of new formulations. In addition to GMP  conditions applied
during production, good quality control analyses should include
both chemical ﬁngerprints and biological ﬁngerprints of botanicals.
6. FDA regulatory requirements
The FDA’s Guidance for Industry: Botanical Drug Products forms
the basis for development of botanicals in the United States. This
guidance describes regulatory approaches that must be followed
in order to market a botanical in the United States. Generally, a
botanical may  be marketed as a dietary supplement, under an over-
the-counter (OTC) drug monograph, or through approval of a New
Drug Application (NDA). All botanicals sold in the US  as dietary
supplements are regulated under the Dietary Supplement Health
and Education Act of 1994 (DSHEA). The DSHEA regulations do not
allow statements that “claim to diagnose, mitigate, treat, cure or
prevent a speciﬁc disease or class of diseases.” If a botanical product
is intended for use in diagnosing, mitigating, treating curing, or
preventing disease, it must be marketed under an approved NDA
or via FDA’s OTC drug monograph system.
There are three approval criteria raised in the FDA’s 2004 guid-
ance for botanical medicine: (1) safety in human use; (2) efﬁcacy
in indicating disease; (3) consistency in batch-to-batch drug qual-
ity. Any botanicals that can document safety and efﬁcacy through
historical usage will be able to move to the clinical trial stage of
development 30 days after submission of an IND (Investigational
S.-H. Liu, Y.-C. Cheng / Journal of Ethnopharmacology 140 (2012) 614– 623 621
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ew Drug), unless directed otherwise by the FDA. The regulatory
olicies of botanical drug products are not as strict as those for con-
entional chemical entities in the IND stage. Differences include
1) no pre-clinical animal studies are required for botanicals prior
o the IND application; (2) botanicals with historical documenta-
ion of safe use in humans do not require phase I clinical trials and
an proceed directly into clinical phase II clinical trial. Satisfactory
cceptance of the IND by the FDA is required for both botanicals and
onventional drugs prior to the initiation of clinical trials. Although
he animal data is not required for IND submission, it may  be needed
or ﬁnal marketing approval (Wu et al., 2004).
In contrast to the policies of the EMEA (European Medicines
valuation Agency) or Canadian regulatory authorities, the US FDA
onsiders botanical drugs to be in the same category as nonbotan-
cal drugs (Wu et al., 2004). This means that botanical drugs are
ubject to the same rigorous quality standards and requirements
or rigorous clinical data for NDA approval in the U.S. Although
he majority of herbal medicine studies have claimed beneﬁcial
ffects in clinical outcome such as survival, tumor response, and/or
uality of life in cancer patients when used alone or as an adju-
ant therapy with conventional therapies, most clinical studies
uffer from less than rigorous design and the quality of the herbal
edicine is unclear. The elucidation of statistical signiﬁcance when
he study drug is compared to current standard therapy is a major
hallenge in pharmaceutical drug development in general; this is
specially true in the case of complex herbal preparations. The
ntire concept of Good Clinical Practice (GCP) must also be incor-
orated into herbal medicine development. An appropriate phase
II double blind, randomized, placebo controlled study with a large
atient population is required to receive herbal medicine market-
ng approval by the regulatory agencies. These strict regulations
ill be applied to PHY906 as well as to any other drug.
Another challenge for PHY906 development at today is the
equirement of the so-called “combination rule.” The applicability
f combination drug regulations to botanical drugs is considered
n the FDA’s 2004 guidance. In essence, these regulations state that
hen drugs are used in combination, each component or active
ngredient must be shown to contribute to the claimed effects of
he combination before marketing approval will be granted. Botan-
cal drug products that are derived from a single part (stem, leaves,
oots, etc.) of a plant, or from a single species of alga or macro-
copic fungus, are not considered to be ﬁxed-combination drugsol for PHY906.
within the meaning of the combination drug regulations. Currently,
however, botanical drugs are subjected to the combination drug
requirements. For traditional Chinese medicines, the latter require-
ment would be extremely problematic. The FDA is considering
revising its regulations to allow for the exemption of botanical
drugs, such as PHY906, under certain circumstances (Chen et al.,
2008; Chen, 2011).
As noted above, quality control is a major challenge in bring-
ing herbal medicines into mainstream medicine. It is important to
assure that future marketed herbal batches have the same thera-
peutic effects as those observed in clinical trials. Traditional Chinese
medicine (TCM) is based often on the use of multiple herbs, or parts
of different herbs, in combination; particular active substances are
not extracted from the herbs, puriﬁed, and then used as individual
drugs as is the case in western medicine (e.g. taxol, originally puri-
ﬁed from the bark of the paciﬁc yew tree). In the case of PHY906,
parts from four different herbs are employed. Analytical methods
have revealed that the PHY906 formulation contains more than 100
different phytochemicals. Some of these phytochemicals have been
deﬁnitively identiﬁed, some tentatively identiﬁed, and others are
of unknown chemical structure, even after rigorous attempts to
identify them over several years of investigation. The FDA, in its
recent publication, noted that it is not required for sponsors to fur-
ther purify or identify the active ingredients of botanical products.
In addition, the FDA has released a draft guidance outlining a path
toward developing combinations of unapproved drugs may  allow
for the possibility that the combination rule may  be waived (Dolgin,
2011). Such new regulations would accelerate the development of
herbal medicines, such as PHY906, in the United States.
7. Summary
From a preclinical point of view, PHY906 is probably one of the
most extensively studied herbal medicines to date. In addition, the
PHY906 formulation has been used in Chinese medicine for over
1800 years to treat a variety of ailments, most notably gastroin-
testinal distress, e.g. diarrhea, nausea, and vomiting. PHY906, when
used as a chemotherapeutic adjuvant, has shown, both in preclini-
cal models and in clinical studies, to have beneﬁcial effects on the
outcomes of advanced colorectal, liver, and pancreatic cancers. In
clinical trials, the addition of PHY906 to conventional chemother-
apy has indicated the high probability of increased survival, tumor
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esponse and/or better quality of life as compared to those seen
ithout PHY906.
A major challenge in pharmaceutical drug development is to
etermine how to show a statistical signiﬁcance in comparison to
he current standard therapy in clinical trials; PHY906 is not exempt
rom this challenge. With the exception of the initial study in
olorectal cancer, clinical studies with PHY906 have lacked appro-
riate control arms. In order for PHY906 to meet the challenge
oted above, an appropriate phase II and III double blind, random-
zed, placebo-controlled study with sufﬁcient patient population
ill be required for PHY906 to receive marketing approval by reg-
latory authorities.
Quality control is a major issue when developing herbal
edicines. However, this issue has been resolved, for the most
art, in the case of PHY906. A multi-faceted quality control platform
as been developed for PHY906 that incorporates detailed LC/MS
nalyses as well as genomics and proteomics. This state-of-the-art
uality control platform makes PHY906 a consistent pharmaceu-
ical grade product. It is important to have both Good Agricultural
ractices (GAP) and Good Manufacturing Practices (GMP) fully in
lace for the production of PHY906 before pivotal phase III clinical
rials can be undertaken.
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